- Home
- NCI vs SNGX Comparison
NCI vs SNGX Comparison
Compare NCI & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCI
- SNGX
- Stock Information
- Founded
- NCI 1992
- SNGX 1987
- Country
- NCI Hong Kong
- SNGX United States
- Employees
- NCI N/A
- SNGX N/A
- Industry
- NCI
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- NCI
- SNGX Health Care
- Exchange
- NCI NYSE
- SNGX Nasdaq
- Market Cap
- NCI 7.4M
- SNGX 6.5M
- IPO Year
- NCI 2024
- SNGX 1987
- Fundamental
- Price
- NCI $2.06
- SNGX $1.36
- Analyst Decision
- NCI
- SNGX
- Analyst Count
- NCI 0
- SNGX 0
- Target Price
- NCI N/A
- SNGX N/A
- AVG Volume (30 Days)
- NCI 173.5K
- SNGX 2.7M
- Earning Date
- NCI 07-22-2025
- SNGX 08-08-2025
- Dividend Yield
- NCI N/A
- SNGX N/A
- EPS Growth
- NCI 67.70
- SNGX N/A
- EPS
- NCI 0.26
- SNGX N/A
- Revenue
- NCI $30,340,230.00
- SNGX $2,342.00
- Revenue This Year
- NCI N/A
- SNGX N/A
- Revenue Next Year
- NCI N/A
- SNGX N/A
- P/E Ratio
- NCI $7.74
- SNGX N/A
- Revenue Growth
- NCI 35.28
- SNGX N/A
- 52 Week Low
- NCI $1.40
- SNGX $1.09
- 52 Week High
- NCI $9.00
- SNGX $7.61
- Technical
- Relative Strength Index (RSI)
- NCI N/A
- SNGX 41.74
- Support Level
- NCI N/A
- SNGX $1.24
- Resistance Level
- NCI N/A
- SNGX $1.39
- Average True Range (ATR)
- NCI 0.00
- SNGX 0.14
- MACD
- NCI 0.00
- SNGX 0.01
- Stochastic Oscillator
- NCI 0.00
- SNGX 34.18
About NCI NEO-CONCEPT INTL GRP HLDGS LTD
Neo-Concept International Group Holdings Ltd is a company that is a one-stop apparel solution services provider. The company offers a full suite of services in the apparel supply chain, including market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management serving customers located in the European and North American markets.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).